Program
HB0034
A development code.
Its studies are mostly in Psoriasis, led by Shanghai Huaota Biopharmaceutical.
Furthest: phase 3, since Jun 22, 20245 company-led studies, 3 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Shanghai Huaota Biopharmaceutical | 53 open or running | phase 3since Jun 22, 2024 | Sep 22, 2021 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 22, 2021First study: phase 1 study in HealthyFirst studyNCT05064345 · 56 enrolled · New Zealand
- Aug 22, 2022Phase 1 study in PsoriasisNCT05512598 · 9 enrolled · China
- Jan 21, 2024Phase 2 study in PsoriasisNCT06231381 · 33 planned · China
- Jun 22, 2024Phase 3 study in PsoriasisNCT06477536 · 33 planned · China
- Nov 29, 2024Phase 1 study in HealthyNCT06716151 · 60 planned · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06716151Healthy · China | 1 | Recruiting | Nov 20, 2025 | 60 |
| NCT06477536Psoriasis · China | 3 | Recruiting | Dec 30, 2025 | 33 |
| NCT06231381Psoriasis · China | 2 | Recruiting | Feb 13, 2025 | 33 |
| NCT05512598Psoriasis · China | 1 | Completed | Nov 15, 2023 | 9 |
| NCT05064345Healthy · New Zealand | 1 | Completed | Sep 1, 2022 | 56 |
How it is read
Names in the registry
- “HB0034”, 5 entries
Codes read as this program: HB0034.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.